The prognosis of patients with advanced Sq-NSCLC is poor and immune checkpoint inhibitors (pembrolizumab, atezolizumab, or cemiplimab in tumors with PD-L1 expression≥50%; pembrolizumab plus carboplatin/nab-paclitaxel chemotherapy or nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy regardless of PD-L1 expression) are the only first line systemic therapies approved by both the FDA (US Food and Drug Administration) and the EMA (European Medicines Agency) (2). Here, CD274 is linked to non-small cell lung carcinoma.